NASDAQ:ANIP - Nasdaq - US00182C1036 - Common Stock - Currency: USD
57.94
-1.73 (-2.9%)
The current stock price of ANIP is 57.94 USD. In the past month the price decreased by -1.28%. In the past year, price decreased by -2.01%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.62 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 642 full-time employees. The company went IPO on 2000-05-04. The firm is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The firm has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.
ANI PHARMACEUTICALS INC
210 Main Street West
Baudette MINNESOTA 56623 US
CEO: Nikhil Lalwani
Employees: 642
Company Website: https://www.anipharmaceuticals.com/
Investor Relations: https://investor.anipharmaceuticals.com
Phone: 12186343500
The current stock price of ANIP is 57.94 USD. The price decreased by -2.9% in the last trading session.
The exchange symbol of ANI PHARMACEUTICALS INC is ANIP and it is listed on the Nasdaq exchange.
ANIP stock is listed on the Nasdaq exchange.
11 analysts have analysed ANIP and the average price target is 77.11 USD. This implies a price increase of 33.09% is expected in the next year compared to the current price of 57.94. Check the ANI PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ANI PHARMACEUTICALS INC (ANIP) has a market capitalization of 1.22B USD. This makes ANIP a Small Cap stock.
ANI PHARMACEUTICALS INC (ANIP) currently has 642 employees.
ANI PHARMACEUTICALS INC (ANIP) has a support level at 54.32 and a resistance level at 59.32. Check the full technical report for a detailed analysis of ANIP support and resistance levels.
The Revenue of ANI PHARMACEUTICALS INC (ANIP) is expected to grow by 25.55% in the next year. Check the estimates tab for more information on the ANIP EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ANIP does not pay a dividend.
ANI PHARMACEUTICALS INC (ANIP) will report earnings on 2025-02-27, after the market close.
The PE ratio for ANI PHARMACEUTICALS INC (ANIP) is 12.68. This is based on the reported non-GAAP earnings per share of 4.57 and the current share price of 57.94 USD. Check the full fundamental report for a full analysis of the valuation metrics for ANIP.
The outstanding short interest for ANI PHARMACEUTICALS INC (ANIP) is 13.07% of its float. Check the ownership tab for more information on the ANIP short interest.
ChartMill assigns a technical rating of 4 / 10 to ANIP. When comparing the yearly performance of all stocks, ANIP turns out to be only a medium performer in the overall market: it outperformed 41.95% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to ANIP. ANIP has only an average score on both its financial health and profitability.
Over the last trailing twelve months ANIP reported a non-GAAP Earnings per Share(EPS) of 4.57. The EPS increased by 2.01% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 1.09% | ||
ROA | 0.59% | ||
ROE | 1.75% | ||
Debt/Equity | 1.44 |
ChartMill assigns a Buy % Consensus number of 84% to ANIP. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 8.19% and a revenue growth 25.55% for ANIP